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FORMULATION, ENANTIOMERIC ASSAY, SHELFLIFE
AND PHARMACOLOGY
Adriaan A. van Sorge, Peter H. Wijnen, Jan L. van Delft,
Valérie M.W. Carballosa Coré-Bodelier and Nicolaas J. van Haeringen
Derived from Pharm World Sci 1999;21:91-5
ABSTRACT
Aphakic cystoid macula edema, occurring after cataract extraction is ascribed to
trauma-induced production of intra-ocular prostaglandins. Sufficient experimental
and clinical evidence supports the use of prostaglandin synthesis inhibitors to coun-
tervail this clinical condition. The active S(+) enantiomer of flurbiprofen, a
prostaglandin synthesis inhibitor, has been formulated into a stereoselective, bal-
last free eyedrop solution in a concentration of 0.015%. Analysis by capillary zone
electrophoresis shows shelflife stability up to four years at room temperature of this
enantiomer. The inhibitory effect on the synthesis of prostaglandins as measured
on a homogenate of bovine iris/ciliary body, remained unaffected during a shelflife
period of three years.
INTRODUCTION
Following cataract surgery non-specific inflammatory responses are induced,
caused by surgical trauma. In the animal model of ocular trauma it is well substan-
tiated that the greater part of this inflammatory process is based on synthesis of
prostaglandins by iris tissue (1,2). The prostaglandins are released into the aque-
ous humor and cause breakdown of the blood aqueous barrier, characterized by
influx of plasma proteins. Diffusion of prostaglandins through the vitreous to the
posterior segment of the eye, may cause breakdown of the blood retinal barrier
resulting in the development of aphakic cystoid macular edema (3).
Ophthalmic solutions of several nonsteroidal anti-inflammatory drugs (NSAIDs)
are commercially available such as diclofenac (0.1%), indomethacin (0.1%), flur-
biprofen (0.03%), ketorolac (0.5%) and a suspension of indomethacin (1.0%).
Indomethacin 0.1% formulation was incorporated in the Dutch National Formulary
(FNA) in 1986. Inpracticalities with indomethacin in aqueous solution - no sterilisa-
tion possibility and only a short shelflife when in solution (4-7) - prompted us to
investigate the possibility in formulating an eyedrop based on flurbiprofen (8). An
official monograph on Flurbiprofen sodium ophthalmic solution is mentioned in the
USP XXIII . The solubility of flurbiprofen (pKa 4.22) in its acid form is 100mg/L at pH
5.0; its sodium salt has a solubility of 400mg/L (26°C, pH 7).
Shortly after it was recognized that inhibition of prostaglandin synthesis could be
the main mechanism of action of NSAID's (9), analysis of the category of 2-aryl pro-
pionic acids (profens] revealed their nature to be racemic and their inhibitory acti-
vity almost exclusively residing in the S-stereoconfiguration (10). However only in
1990 the ocular effect of topically applied S(+) ibuprofen was reported in a rabbit
model of interleukin-1 (11) and paracentesis induced uveitis (12] at relatively high
concentrations (0.9% and 0.8% respectively). Also with S(+) naproxen, marketed
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by Syntex as enantiomeric pure NSAID, the antiinflammatory effect in eyedrops
(0,5%) was demonstrated experimentally (13). In a bovine iris/ciliary body
homogenate incorporating the cyclooxygenase -1 (COX-1) enzyme, the S(+) flur-
biprofen proved to be the pharmacological active moiety, showing 100 times greater
potency than  R(-) flurbiprofen in inhibiting prostaglandin synthesis (14).
In keeping with the benefits of only using the proposedly active moiety, (S+) flur-
biprofen, we investigated formulations, containing the pure enantiomers of flurbipro-
fen (15). We thereby avoid isomeric ballast, providing a reduction in metabolic load
to the patient. Advantages would eventually be: less complex pharmacokinetic pro-
files (16), less complex drug interactions and uncomplicated concentration-effect
relationships. The present study deals with the formulation, analysis, keeping quali-
ty and pharmacology of solutions containing 0.03% flurbiprofen, 0.015% flurbiprofen
(S+) or flurbiprofen (R-) 0,015%, all three based on their acid form.
MATERIALS AND METHODS
Drugs and chemicals
Flurbiprofen, (S+)flurbiprofen and (R-)flurbiprofen were purchased from Duchefa
Pharma BV (Haarlem, The Netherlands). Disodiumphosphate.2H2O, Potassium-
dihydrogen-phosphate were purchased from Bufa (Uitgeest, The Netherlands).
USP reference standard, USP 2-(4-Biphenylyl)propionic acid RS, (Flurbiprofen
related compound A limit test; catalog number: 28576 ).
Vancomycin hydrochloride was purchased from Sigma (St Louis, Mo, USA).
H3PO4, KH2PO4, TRIS and Na2HPO4 were analytical grade and obtained from JT
Baker (Deventer, The Netherlands).Water for injections USPXXIII (Fresenius, 's-
Hertogenbosch, The Netherlands). Water for analysis was purified in an Alpha-Q
apparatus (Millipore, Bedford, MA,USA). Samples of the speciality Ocuflur® (0.03%
flurbiprofen sodium, lotnumbers: 94G11 exp:01/96, 96L18 exp: 06/98 and 99K29
exp: 05/2001) were a gift from Allergan (Belgium).
Formulation of eyedrops
The formulation for the 0.13M phosphate buffer, pH 7.4 and osmolality of 290
mOsmols/kg is based on previous work with indomethacin (7)
Composition of buffersolution
Disodiumphosphate. 2H2O 20 gram
Potassiumdihydrogenphosphate 3   gram
Water for injections ad 1 Liter
This solution is filtered through a 0.22 micron filter before sterilization for 15 minutes
at 121°C. This buffersolution is used for preparing the eyedrops for pharmacological
testing and for the shelflife procedure.
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Preparation of the racemic, (S+)- and (R-) flurbiprofen eyedrops proceeds by addi-
tion of respectively 30 mg  racemic flurbiprofen and 15 mg of each of the enan-
tiomers to 100 ml of phosphatebuffer solution. The final pH remaining unchanged
at 7.4, because the relatively low concentration of flurbiprofen (1.2mM) does not
burden the buffer (130mM) significantly. All flurbiprofen preparations were stored in
glass containers. No preservative is added to the final solution as the eyedrops will
be used prior to cataract surgery and eye-surgeons show preference to use eye-
drops, if feasable, without unnecessary additions thereby avoiding possible allergic
reactions.
For shelflife testing, preparations were either 0.22 micron filtered, heat treated at
100°C for 60 minutes or sterilized at 121°C for 15 minutes.
Preparations were stored for a period of up to 60 months, either at room tempera-
ture in subdued light or at - 20°C. Analysis was performed by capillary zone elec-
trophoresis (CZE) on samples at t=0 and samples stored for 36, 48 and 60 months.
All concentrations complied with the requirement of containing between 90 - 110%
of the active moiety and were set at 100% at the start of shelflife analysis.
Additional analysis was done, according to the monographs on Flurbiprofen men-
tioned in the USP24-NF19, European Pharmacopea 1999 and the British
Pharmacopea 2000, on Flurbiprofen related substances of which 2-(4-




CZE is a technique which permits high separation efficiencies combined with small
sample volumes. Quantitative aspects of  CZE methods for enantiomeric purity test-
ing are discussed in the literature for both basic and acidic drugs. Depending on the
resolution of the peaks, limits of detection of <0.1% are shown for determination of
the minor enantiomer  (17-20).
An applied Biosystems (San Jose, CA, USA) Model 270A-HT CZE system was
used, equipped with a variable-wavelength UV absorbance detector (254 nm, 0.5
second rise time). The separations were performed in a fused silica capillary (70 cm
x 50 µm inner diameter, Polymicro Technologies, Phoenix, AZ, USA) with a length
of 50 cm to the detection window. The electrophoresis buffer was prepared by
adjusting a 50mM KH2PO4 solution to pH=6.0 with a 50 mM Na2HPO4 solution. The
glycopeptide antibiotic Vancomycin was used as chiral selector (21-23). The selec-
tor was added to the inlet buffer only, at a concentration of 0.6mM. 
The separations were carried out at +15 kV, with the oven temperature set at
30°C. Samples were introduced into the capillary at the anodic end via a controlled
vacuum injection system of 1 or 2 seconds corresponding to a volume of approxi-
52
Chapter 3
mately 4 - 8 nanoliter, respectively. After sample injections the electrode and the
outer surface of the fused silica capillary were dipped for 0.5 seconds in water for
cleansing. Analytes are detected in the capillary near the cathode. Data were
recorded using a Fisons Model VG-Multichrom system.
Enantiomeric assay
Chiral separation occurs through selective complexation of the flurbiprofen enan-
tiomers with vancomycin. From the corrected peak areas of the enantiomers, the
enantiomeric ratio (E.R.) was calculated as R(-)/S(+). To determine if racemization
occurred during storage conditions the E.R. was determined in all samples. The
racemic drug will have an enantiomeric ratio of unity. For the S(+) and R(-) samples
the impurities are calculated as percentage relative to the main optical isomer. The
racemic samples under investigation were injected after appropriate dilution.
Phosphate buffer, used in the formulation of the eyedrops, was injected as blank
solution to rule out interference.
Quantitative assay
For quantitative determination of the S(+) and R(-) samples the above described
system was changed for analysis of total flurbiprofen. The CZE-buffer was stabi-
lized to pH 7 and consisted of 40mM TRIS/H3PO4 solution without chiral selector.
S(+) and R(-) flurbiprofen migrate as one peak, thus minimizing the contribution of
integration errors on the quantitative results. Separations were carried out at +25
kV. Samples were analyzed in duplo and on two separate days. The racemic sam-
ples and the S(+) and R(-) samples were appropriately diluted before injection.
Standards were injected at the beginning, halfway and at the end of the sample
sequence. Calibration was taken into account by insertion of standards in the same
concentration range during the analysis. The phosphate buffer was included as
blank for investigation of possible interferences.
B
A test on common impurities can be performed according to the monographs on
Flurbiprofen (Sodium) described in the European Pharmacopea (1999 page 859-
61), the USP24-NF19 (effective january 2000) and the British Pharmacopea  (2000
page 718) To perform a limit test on 2-(4-Biphenylyl)propionic acid (Flurbiprofen
related compound A), the main impurity, a  liquid chromatography system was
equipped with a variable-wavelength UV absorbance detector set at 247 nm and a
chrompack Inertsil 5 octadecylsilyl-3 column (catalog number CP28308).  As the
mobile phase, at a flow rate of 1.0 ml/min, a mixture of 5 volumes of glacial acetic
acid, 35 volumes of acetonitrile and 60 volumes of water was used. Injection vol-
ume used was 20 microliter with a relative standard deviation for replicate injections
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of less than 1%. The resolution factor between the two principle peaks is larger than
1.5 (1.94) and accords with the requirements set by the British Pharmacopoeia,
European Pharmacopoeia and USP24-NF19. The relative retention time for flur-
biprofen related compound A to flurbiprofen is 0.87 (figures 1a and 1b). Sampling
on several batches of flurbiprofen S(+) 0.015%, flurbiprofen R(-) 0.015% and of
Ocuflur® (0.03% flurbiprofen sodium) was performed.
Figure 1a. Analysis of Ocuflur® (batch 96L18)  for Flurbiprofen related compound A.





Inhibition of prostaglandin synthesis by flurbiprofen was performed using bovine
iris/cilliary body homogenate according to Van Sorge et al (14). In brief, 25 µL of
flurbiprofen solution is added to 100 µL of iris/ciliary body homogenate, prepared
from one iris/ciliary body in one ml of 0.05 M TRIS buffer pH 7.4. The enzyme reac-
tion was stopped by heating for 3 minutes in boiling water. In the supernatant after
centrifugation PGE2 was determined using an enzyme immune assay. Inhibition of
PGE2 release was calculated by the difference of PGE2 release in the absence and




On injection of the phosphate buffer used in the formulation of the eyedrops no
interfering peaks were detected. The E.R. of the flurbiprofen standard was 0.999 ±
0.006 (n=6) which corresponds to 50.0 ± 0.2%.
Stored samples of racemic flurbiprofen displayed no change in E.R. as compared
to standard. Neither a heat treated sample at 100°C and stored at roomtempera-
ture for 60 months (E.R.: 0.996), nor a second sample of the same date sterilized
for 15 minutes at 121°C and stored at room temperature (E.R.: 0.997) showed sig-
nificant deviation in E.R from the standard racemic flurbiprofen (E.R. 0.999).
Samples of 48 months storage at roomtemperature (E.R.: 0.996) and 24 months at
-20°C (E.R.: 0.995) exhibited no change in E.R. as compared to standard. Ocuflur®
(lotnumber 94G11) stored at room temperature (36 months) showed no change in
E.R. (0.995).
All samples of S(+) flurbiprofen (48 months or less and stored at room tempera-
ture) showed no R(-) enantiomer above limit of detection of the assay, which is
approximately 0.1%.
The racemic moiety of S(+) in R(-) flurbiprofen at t=0 was determined as 0.7% ± 0.1
(n=3). In Figure 2 the electropherograms are shown for two samples of R(-) flur-
biprofen, after storage at -20°C for 48 months without sterilization as well as after
storage for 48 months at roomtemperature after sterilization. The presence of S(+)
flurbiprofen in the R(-) storage samples (48 months at room temperature sterilized
at 15 minutes 120°C) increased to 0.9% (n=2).
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Figure 2. Comparison of two superimposed electropherograms of R(-) flurbiprofen samples:
(A) stored at roomtemp, sterilized; (B): not sterilized stored at -20 ºC.
Quantitative analysis
S(+) flurbiprofen samples irrespective of heat treatment and storage at roomtem-
perature for 48 months showed a maximum decline to 93% of declared value of the
active moiety. The R(-) flurbiprofen samples revealed the same degradation char-
acteristics as those for S(+). Ocuflur® stored at roomtemperature showed a decline
to 92% of the declared value after 36 months while racemic flurbiprofen samples,
irrespective of heat treatment showed a maximum decline to 90% in 48 months.
The type of degradation reaction involved was not investigated. In the electro-
pherogram no extra signals are detected, but in the set-up used only negative
charged components with UV-absorbance at 254 nm would be visible.
Analysis of Flurbiprofen related compound A (Limit test)
Impurities can be found in compendial articles. According to the European
Pharmacopoeia 3e Edition 2001 Flurbiprofen has five identified impurities. One of
these is known as flurbiprofen related compound A and is used for the limit test.
This substance in it self is a stereoisomer but is available as a racemic reference





Table 1. Flurbiprofen related compound A content in ophtalmic solutions.
Preparation Sterilized Date of manufacturing ‰ Flurbiprofen
15 min 121°C related compound A
S(+)Flurbiprofen 0.015%     Y 28-08-95 0,9; 1,0
N 28-08-95 1,3 ; 1,3; 0,9; 0,8
Y 08-10-93 0,5; 0,5; 0,6; 1,03
R(-)Flurbiprofen 0.015% Y 08-10-93 0,9; 0,8
N 08-10-93 0,3; 0,4
Y 28-08-95 0,2; 0,2
N 28-08-95 0,2; 0,2
Ocuflur®* Y 94G11 2,5; 2,9
Y 96L18 3,7; 3,6
Y 99K29 2,5; 2,5; 2,6; 2,3
* Flurbiprofen Sodium. 2H2O 0.03%. Y=yes, N=No.
In either case the products agreed with the Pharmacopoeial limits for the known impurity Flurbiprofen
related compound A (5‰),  being stored at room temperature and irrespective of heat treatment. 
In Table 1 the results are presented not only for the batches prepared with  the flur-
biprofen isomers as ophthalmic solution but also for the racemic flurbiprofen spe-
cialty Ocuflur®. The ophthalmic solutions of isomeric flurbiprofen have been
analysed with the same maximum storage time as was stated under enantiomeric
analysis.
PHARMACOLOGICAL ANALYSIS
Samples of flurbiprofen (R-) and flurbiprofen (S+) retained their inhibitory effect on
prostaglandin synthesis during the period (36 months at room temperature) of
shelflife analysis. This appeared from identical concentration inhibition curves
using bovine iris/ciliary body homogenate (results not shown) as compared with
freshly prepared solutions (Figure 3). The ratio of 100 in inhibitory potency for S(+)
flurbiprofen vs. R(-) flurbiprofen also remained unchanged as appears from the un-
changed IC50 of 10-8 M for S(+) flurbiprofen and of 10-6 M for R(-) flurbiprofen. 
Figure 3. Concentration-response curves for inhibition of prostaglandin synthesis in bovine
iris/ciliary body homogenate by racemic flurbiprofen (∇), R(-)flurbiprofen (O), and S(+)flur-
biprofen () (derived from reference 14). Concentrations of flurbiprofen are final concen-
trations in the assay mixture. For racemic flurbiprofen the concentration values are given in
concentrations of the individual enantiomers. Each point represents the average ± S.E.M.
of four to six determinations from different pools of bovine iris/ciliary homogenates.
DISCUSSION
The formulation of an eyedrop, like indomethacin based on a previously published
phosphate buffer at pH 7.4 (7), is possible for flurbiprofen. Due to the racemic
nature of the molecule and the current national and supranational policies (24) to
require quality, safety and efficacy on medicinal products it was deemed necessary
to exploit every possibility to formulate an eyedrop that was free of enantiomeric
ballast and only contained the pharmacologically active moiety, S(+) flurbiprofen. 
The first reports on use of indomethacin as an effective eyedrop to combat mac-
ula edema after cataract surgery were reassuring but were impractical in pharma-
ceutical sense. Short shelflife of indometacin when in aqueous solution, uncertain-
ty of the real available concentration when provided as a suspension and irritating
when applied as an oily solution. The available specialties that have arrived on the
Dutch market are not the satisfactory solution for this clinical entity. Indoptol® con-
tains the irritating substance phenylethanol and also benzalkoniumchloride the lat-
ter which can react with indomethacin to form insoluble complexes that will remain
unnoticed in a suspension. Indocollyre® incorporates the for the eye unpleasant
substance methylparahydroxybenzoate and measures a high osmolality when
brought in to solution (approximately 1500 mOsm/kg).
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The shelflife analysis of a stereospecific ballast free flurbiprofen eyedrop formula-
tion was carried out by CZE. To rule out pitfalls as in vitro racemization, analysis
was performed of the enantiomeric ratio of flurbiprofen during the shelflife period.
The observed decline in flurbiprofen was not supported by observation of degrada-
tion products in the electropherograms. This does not rule out any degradation, as
only UV-active negatively charged compounds within the chosen run time would be
detected. During the investigative period no evidence was found of in vitro inver-
sion. The shelflife determination of S(+) flurbiprofen has shown the solution to be
stable in glass containers for 48 months (Ocuflur® 36 months in durable plastic
container) when one adheres to the limits of maximum 10% degradation. The con-
centration limit for the known impurity USP 2-(4-Biphenylyl)propionic acid RS has
not been exceeded in any of the investigated samples. The enantiomeric inversion
of R(-) flurbiprofen to the pharmacologically active S(+) flurbiprofen as observed in
several species (25) has been ruled out in our assay using homogenates of bovine
iris/ciliary body (14). In human blood no chiral inversion could be detected (26).
Metabolism of flurbiprofen does not occur in ocular tissues as appeared from expe-
riments in rabbits using radioactive labelled material (27).
In the pharmacological assay we investigated the potency of racemic flurbiprofen
and the separate enantiomers S(+) and R(-) to inhibit the bovine iris/ciliary body
cyclooxygenase-1 enzyme in producing prostaglandin E2 (14). The S(+) moiety dis-
played 50% prostaglandin synthesis inhibition at a concentration of 10-8M (IC50).
Extrapolation of  in vivo data on the ocular  bioavailability of ophthalmic racemic flur-
biprofen shows that our present data on the IC50 (10-8M) for inhibition of
prostaglandin synthesis by S(+) flurbiprofen fall well within the concentrations of
flurbiprofen, available in aqueous humor and shown to be effective in the eye after
application to the outer eye (Table 2).
Table 2. Dose/concentration relationships of racemic flurbiprofen in rabbit and human eye.
Flurbiprofen (nmol) Flurbiprofen (M)
Instilled dose in aqueous humor
400*              (rabbit) 800 x 10-8*
10 (ID50)** (rabbit) 20 x 10-8***
50****        (human) 25 x 10-8****
*Values derived from (28), **average value for protein and fluorescein influx, derived from (8), 




Investigation of the dose-response inhibition curves (8) reveals that racemic flur-
biprofen with a concentration of 0.03% produces near maximal effect on the break-
down of the blood-aqueous barrier and this will also pertain to our stereospecific
ophthalmic solution of 0.015%. In contrast to our study the flurbiprofen eyedrops
used in clinical investigations or marketed specialities are composed of flurbiprofen
sodium 0,03%. Flurbiprofen sodium complying to pharmacopoeial standards repre-
sents the dihydrate and therefore 0,03% is equivalent to only 0.024% flurbiprofen
acid, or 0.012% S(+) flurbiprofen acid.
CONCLUSIONS
Analytical and pharmacological evidence is provided that eyedrops with a mere
0.015% flurbiprofen S(+) should suffice for meeting the indications for ophthalmic
use and justifies its use as ballast free stereo specific drug. The shelflife of these
eyedrops can be put at four years when supplied in a glass container. For a com-
mercially available eyedrop (i.e. Ocuflur®, durable plastic eye drop container) three
years is more appropriate.
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